TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31965610

Group type: EXPERIMENTAL
Intervention: Surgical management (placement of a single 3.5-mm lag screw under arthroscopic guidance)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 47
Study: 30286028

Group type: EXPERIMENTAL
Intervention: Animal model
Number of subjects: 46

Group type: COMPARATOR
Intervention: Blue Phantom models
Number of subjects: 46
Study: 27237088

Group type: EXPERIMENTAL
Intervention: Monitoring wires attached (with electrodes)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No monitoring wires attached (without electrodes)
Number of subjects: 228
Study: 25313586

Group type: EXPERIMENTAL
Intervention: SMS group (n=195)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control group (n=193)
Number of subjects: 388
Study: 22137686

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional petroleum gauze dressings (conv)
Number of subjects: 30
Study: 20720134

Group type: COMPARATOR
Intervention: Standard LPS-Flex prosthesis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Gender-specific LPS-Flex prosthesis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 18569991

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 139
Study: 15661109

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg bodyweight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 11
Study: 12614748

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 28
Study: 10232640

Group type: EXPERIMENTAL
Intervention: Transgalactooligosaccharides 15 g/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transgalactooligosaccharides 7.5 g/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0 g/d)
Number of subjects: 40
Study: 8966163

Group type: EXPERIMENTAL
Intervention: Rapid urease‐based test
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Histological staining
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Serology
Number of subjects: 150
Study: 1813313

Group type: EXPERIMENTAL
Intervention: summarization training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: summarization training with a self-monitoring component
Number of subjects: 45

Group type: COMPARATOR
Intervention: traditional instruction
Number of subjects: 45
Study: 6337425

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1000 mg daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 30507211

Group type: EXPERIMENTAL
Intervention: Culturally accommodated treatment (A-CBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard group-based cognitive-behavioral treatment (S-CBT)
Number of subjects: 70
Study: 29503404

Group type: COMPARATOR
Intervention: Pitavastatin 1 mg/day
Number of subjects: 12600

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 12600
Study: 27228270

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Care (Control)
Number of subjects: 0
Study: 24008122

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine combination therapy (150mg aliskiren + 5mg amlodipine for 8 weeks, then 300mg aliskiren + 5mg amlodipine for another 8 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-dose amlodipine monotherapy (10mg amlodipine for 16 weeks)
Number of subjects: 105
Study: 22925922

Group type: EXPERIMENTAL
Intervention: Locator attachment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magfit attachment
Number of subjects: 0
Study: 20036363

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day (early intensive lipid-lowering therapy)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 180
Study: 18580483

Group type: COMPARATOR
Intervention: PEEP 0 mbar
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PEEP 5 mbar
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PEEP 10 mbar
Number of subjects: 39
Study: 16205071

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 69
Study: 11845337

Group type: EXPERIMENTAL
Intervention: Early mobilization (physiotherapy)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard therapy (soft cervical collar)
Number of subjects: 168
Study: 10430396

Group type: EXPERIMENTAL
Intervention: Eradication therapy (Pantoprazole 40 mg daily, Amoxycilline 1000 mg b.i.d., Clarithromycine 500 mg b.i.d.)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 251
Study: 7638662

Group type: EXPERIMENTAL
Intervention: Radiologic findings
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clinical findings
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sagittal diameter changes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiologic subgroups of stenosis
Number of subjects: 100
Study: 2178390

Group type: EXPERIMENTAL
Intervention: Pasta cooked for 11 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pasta cooked for 16.5 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pasta cooked for 22 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonmethane producers
Number of subjects: 12
Study: 6110818

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine given one month after hepatitis B immune globulin injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine and immune globulin given simultaneously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hepatitis B vaccine given alone
Number of subjects: 60
Study: 31975547

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (60 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest without food consumption
Number of subjects: 10
Study: 29802172

Group type: EXPERIMENTAL
Intervention: Added angiographic embolisation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 241
Study: 27745536

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Completion of CBT element homework assignments
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 115
Study: 26564292

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% alcohol
Number of subjects: 388

Group type: COMPARATOR
Intervention: 10% povidone‐iodine
Number of subjects: 388
Study: 24289099

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help book
Number of subjects: 0
Study: 21244861

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 19303145

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire (SAQ)
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: SAQ with audio (AASI)
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Interviewer-administered questionnaire (IAQ)
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted survey instrument (ACASI)
Number of subjects: 1495
Study: 17402320

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting glucose at 110‐140 mg/dl
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional insulin therapy controlling glucose at 140‐200 mg/dl when exceeding 200 mg/dl
Number of subjects: 89
Study: 15488058

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 45
Study: 11210405

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily for 8 days + Almotriptan 12.5 mg on Day 8
Number of subjects: 14

Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg on Day 8
Number of subjects: 14
Study: 10194994

Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 7845558

Group type: EXPERIMENTAL
Intervention: Pantomimed movements directed towards remembered objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural target-directed grasping movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantomimed actions beside a target object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined, familiar objects
Number of subjects: 0
Study: 3051607

Group type: EXPERIMENTAL
Intervention: 6-month regimen of rifampicin and ethambutol (4RE) supplemented by streptomycin and pyrazinamide for the first 2 months
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 9-month regimen of rifampicin and ethambutol (7RE) supplemented by streptomycin and pyrazinamide for the first 2 months
Number of subjects: 226
Study: 31738228

Group type: EXPERIMENTAL
Intervention: Nortriptyline + Morphine combination therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 24
Study: 31037274

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28160545

Group type: EXPERIMENTAL
Intervention: Resistance training (TG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study: 26162657

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Short-term therapies (SPP and SFT)
Number of subjects: 326
Study: 23451806

Group type: EXPERIMENTAL
Intervention: Once-daily prolonged-release mesalazine (4 g/day)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Twice-daily prolonged-release mesalazine (4 g/day)
Number of subjects: 206
Study: 21640780

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 100
Study: 18405442

Group type: EXPERIMENTAL
Intervention: Targeted agents targeting the hypoxia inducible factor-alfa (HIF-) / vascular endothelial growth factor (VEGF) pathway and mammalian target of rapamycin (mTOR) signal transduction pathway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 17786805

Group type: EXPERIMENTAL
Intervention: Participants in the intervention (education of municipality employees)
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Subgroups of non-participants (too ill, not reached)
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Subgroups of non-participants (too healthy, another reason for refusal)
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Non-participants in intervention municipalities
Number of subjects: 5788
Study: 15273470

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.05 mg/kg/day for 1 year
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 11475854

Group type: EXPERIMENTAL
Intervention: DDD pacing mode with optimized AVD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VVI pacing mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Optimal DDD pacing mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VVI pacing mode in CAD and AH + CAD patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conversion from VVI to optimal DDD pacing mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CAD patients with myocardial infarction or AH patients with LV hypertrophy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 10101926

Group type: COMPARATOR
Intervention: Laser Doppler fluxmetry
Number of subjects: 67
Study: 7937568

Group type: EXPERIMENTAL
Intervention: 20 mg clobazam
Number of subjects: 21
Study: 2965154

Group type: EXPERIMENTAL
Intervention: rIFN alpha 2C (2MU) given subcutaneously 5 times per week for 8-12 weeks, then once weekly until week 48.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combined therapy of rIFN alpha 2C (2MU) and medroxyprogesterone acetate (MPA) 750 mg p.o. daily until week 48.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned, but both treatment groups had a median survival of 7 months.
Number of subjects: 93
Study: 31573856

Group type: EXPERIMENTAL
Intervention: Trocar technique
Number of subjects: 105

Group type: COMPARATOR
Intervention: Seldinger technique
Number of subjects: 105
Study: 29649897

Group type: EXPERIMENTAL
Intervention: Community assets (2 assets)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Community assets (3 assets)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Community assets (4 to 5 assets)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: 0 to 1 assets
Number of subjects: 1111
Study: 26477350

Group type: EXPERIMENTAL
Intervention: MRI-specific play therapy intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 24594090

Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway (IG-SGA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Portex Soft Seal Laryngeal Mask (PSS-LM)
Number of subjects: 51
Study: 22744207

Group type: EXPERIMENTAL
Intervention: Outpatient long-term treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 20412877

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (0.2 ml, 6 microg HA per strain, split into two-site injections)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intramuscular vaccination (0.5 ml, 15 microg HA per strain)
Number of subjects: 156
Study: 18546660

Group type: EXPERIMENTAL
Intervention: Tilted ellipses depicting the circular top of a cylinder at angles from 5 degrees to 85 degrees.
Number of subjects: 0
Study: 15957833

Group type: EXPERIMENTAL
Intervention: Triptolide (TL) plus benazepril
Number of subjects: 67

Group type: COMPARATOR
Intervention: Benazepril alone
Number of subjects: 67
Study: 12235694

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 12 months after cessation of chemotherapy
Number of subjects: 41
Study: 10421395

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition plus chemotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 92
Study: 7669306

Group type: EXPERIMENTAL
Intervention: End-tidal isoflurane monitored (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unmonitored group (n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 2160490

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (15 capsules of 1 g fish oil daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil control (15 capsules of 1 g olive oil daily)
Number of subjects: 20
Study: 433814

Group type: EXPERIMENTAL
Intervention: Zinfandel wine (9.3% w/v alcohol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Delacholized Zinfandel wine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pure ethanol (9.3% w/v aqueous solution)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study: 29961138

Group type: EXPERIMENTAL
Intervention: CAF + HA
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 30
Study: 27928660

Group type: EXPERIMENTAL
Intervention: Community-based case management in addition to usual care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 25996365

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulative therapy (SMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham SMT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (SMT and sham SMT)
Number of subjects: 52
Study: 23761412

Group type: EXPERIMENTAL
Intervention: Text-message reminder
Number of subjects: 991

Group type: COMPARATOR
Intervention: Control group (no text-message reminder)
Number of subjects: 991
Study: 21646287

Group type: EXPERIMENTAL
Intervention: Phlebotomy therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 50
Study: 19860612

Group type: EXPERIMENTAL
Intervention: Weekly methotrexate (MTX) and daily 6-mercaptopurine maintenance therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Random determination of serum MTX levels
Number of subjects: 49
Study: 18092436

Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam 0.2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intranasal Ketamine 5 mg/kg
Number of subjects: 50
Study: 15139159

Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT) - running at 40% PRS for 15 minutes after the first pair of treadmill runs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Contrast Temperature Water Immersion (CTW) - alternating between 60-s cold (10 degrees C) and 120-s hot (42 degrees C) water immersion for 15 minutes after the first pair of treadmill runs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive Recovery (PAS) - standing stationary for 15 minutes after the first pair of treadmill runs
Number of subjects: 14
Study: 11602864

Group type: EXPERIMENTAL
Intervention: i.v. ganciclovir
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9641128

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calcium hydroxide (Control)
Number of subjects: 200
Study: 7857503

Group type: EXPERIMENTAL
Intervention: Hypericum extract (3 x 300 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Maprotiline (3 x 25 mg)
Number of subjects: 102
Study: 2573178

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 24
Study: 870015

Group type: EXPERIMENTAL
Intervention: Intracameral injection of 50 microng of gentamicin
Number of subjects: 1626

Group type: COMPARATOR
Intervention: Systemic and topical chloramphenicol prophylaxis (historical control)
Number of subjects: 1626
Study: 31856835

Group type: EXPERIMENTAL
Intervention: Doorstep provision of oral contraceptive pills and condoms
Number of subjects: 3078
Study: 28437597

Group type: EXPERIMENTAL
Intervention: Weight Watchers Online (WWO)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control (online newsletter)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Weight Watchers Online with ActiveLink (WWO+AL)
Number of subjects: 279
Study: 25971607

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 234

Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 234
Study: 24658396

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz cerebellar rTMS, 5 sessions of 15 minutes over 5 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study: 22244705

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for alcohol dependence (12 weeks)
Number of subjects: 77
Study: 19930331

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 17560287

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 4676

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 4676
Study: 15552358

Group type: EXPERIMENTAL
Intervention: Generation (self-produced items)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provided items (control)
Number of subjects: 0
Study: 11906445

Group type: EXPERIMENTAL
Intervention: Spiritual expression (importance rated by patients)
Number of subjects: 112
Study: 9477042

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tab/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 77
Study: 7873471

Group type: EXPERIMENTAL
Intervention: Ranolazine (200 or 500 micrograms/kg body weight)
Number of subjects: 15
Study: 3060511

Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids (budesonide, 100 micrograms in each nasal cavity every 12 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28459795

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE) program, 4 weeks, twice a week, 3 sets of 6-10 repetitions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE) program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 28628003

Group type: COMPARATOR
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: FCM-miniR (fludarabine, cyclophosphamide, mitoxantrone, and low-dose rituximab)
Number of subjects: 206

Group type: COMPARATOR
Intervention: FCR
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: FCM-miniR
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: FCR and FCM-miniR
Number of subjects: 206
Study: 26641632

Group type: EXPERIMENTAL
Intervention: Computer-based exam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-based exam
Number of subjects: 0
Study: 21172506

Group type: EXPERIMENTAL
Intervention: Ischemic mitral regurgitation group (IMR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal mitral valve group (Control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ischemic mitral regurgitation group (IMR) with anterior infarct
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ischemic mitral regurgitation group (IMR) with inferior infarct
Number of subjects: 35
Study: 18926439

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 255